down arrow

China Pharma Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US16941T2033
USD
1.66
-0.14 (-7.78%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.641.80

52 Week

1.203.35
Valuation
Technical
Day's Volume

CASH

1.56 k

Shareholding (Mar 2025)

FII

0.77%

Held by 3 FIIs

DII

99.21%

Held by 0 DIIs

Promoter

0.00%

How big is China Pharma Holdings, Inc.?

22-Jun-2025

As of Jun 18, China Pharma Holdings, Inc. has a market capitalization of 5.97 million and reported net sales of 4.29 million with a net profit of -4.57 million over the latest four quarters.

As of Jun 18, China Pharma Holdings, Inc. has a market capitalization of 5.97 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 4.29 million, while the sum of net profit for the same period is -4.57 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 7.93 million and total assets of 15.07 million.

Read More

What does China Pharma Holdings, Inc. do?

22-Jun-2025

China Pharma Holdings, Inc. is a micro-cap holding company focused on developing, manufacturing, and marketing pharmaceutical products for human use. As of March 2025, it reported net sales of $1 million and a net loss of $1 million, with a market cap of $5.97 million.

Overview: <BR>China Pharma Holdings, Inc. is a holding company engaged in the development, manufacture, and marketing of pharmaceutical products for human use in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 5.97 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.43 <BR>Return on Equity: -63.86% <BR>Price to Book: 0.83<BR><BR>Contact Details: <BR>Address: 2Nd Floor, No. 17, Jinpan Road, Haikou, HAIKOU HAN: 570216 <BR>Tel: 86 898 66811730 <BR>Website: http://www.chinapharmaholdings.com

Read More

Who are in the management team of China Pharma Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of China Pharma Holdings, Inc. includes Zhilin Li (Chairman, President, CEO, Interim CFO), Heung Tsui (Director), and independent directors Gene Bennett, Baowen Dong, and Yingwen Zhang. They oversee the company's operations and strategic direction.

As of March 2022, the management team of China Pharma Holdings, Inc. includes the following individuals:<BR><BR>- Zhilin Li: Chairman of the Board, President, Chief Executive Officer, and Interim Chief Financial Officer<BR>- Heung Tsui: Director<BR>- Gene Bennett: Independent Director<BR>- Baowen Dong: Independent Director<BR>- Yingwen Zhang: Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More

Is China Pharma Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, China Pharma Holdings, Inc. shows a mildly bearish trend with mixed signals from moving averages and indicators, having outperformed the S&P 500 in the short term but underperformed year-to-date.

As of 2 September 2025, the technical trend for China Pharma Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and KST show mild bullishness. Bollinger Bands present a mixed signal with weekly bullishness and monthly mild bearishness. The Dow Theory indicates no trend on a weekly basis and mild bearishness monthly. <BR><BR>In terms of multi-period returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 3.97% and 33.67% respectively, but has significantly underperformed over the longer terms, including a -15.48% YTD return compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 6 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.42

stock-summary
Return on Equity

-55.05%

stock-summary
Price to Book

0.87

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.28%
0%
15.28%
6 Months
0.42%
0%
0.42%
1 Year
-14.87%
0%
-14.87%
2 Years
-74.46%
0%
-74.46%
3 Years
-97.06%
0%
-97.06%
4 Years
-99.29%
0%
-99.29%
5 Years
-99.28%
0%
-99.28%

China Pharma Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is China Pharma Holdings, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for China Pharma Holdings, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and KST show mild bullishness. Bollinger Bands present a mixed signal with weekly bullishness and monthly mild bearishness. The Dow Theory indicates no trend on a weekly basis and mild bearishness monthly. In terms of multi-period returns, the stock has outperformed the S&P 500 over the past week and month, with returns of 3.97% and 33.67% respectively, but has significantly underperformed over the longer terms, including a -15.48% YTD return compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-16.68%
EBIT Growth (5y)
-6.99%
EBIT to Interest (avg)
-3.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
0.54
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.37%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.74
EV to EBIT
-1.89
EV to EBITDA
-3.77
EV to Capital Employed
0.82
EV to Sales
1.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-43.26%
ROE (Latest)
-63.86%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.02%)

Foreign Institutions

Held by 3 Foreign Institutions (0.77%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 11.11% vs -18.18% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 64.29% vs -133.33% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.00",
          "val2": "0.90",
          "chgp": "11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.30",
          "val2": "-0.60",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.50",
          "val2": "-1.40",
          "chgp": "64.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-635.70%",
          "val2": "-1,504.40%",
          "chgp": "86.87%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -35.71% vs -13.58% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -51.61% vs 22.50% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.50",
          "val2": "7.00",
          "chgp": "-35.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.70",
          "val2": "-3.10",
          "chgp": "-51.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,013.20%",
          "val2": "-392.50%",
          "chgp": "-62.07%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1.00
0.90
11.11%
Operating Profit (PBDIT) excl Other Income
-0.30
-0.60
50.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.50
-1.40
64.29%
Operating Profit Margin (Excl OI)
-635.70%
-1,504.40%
86.87%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 11.11% vs -18.18% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 64.29% vs -133.33% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
4.50
7.00
-35.71%
Operating Profit (PBDIT) excl Other Income
-2.00
0.00
Interest
0.20
0.30
-33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.70
-3.10
-51.61%
Operating Profit Margin (Excl OI)
-1,013.20%
-392.50%
-62.07%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -35.71% vs -13.58% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -51.61% vs 22.50% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About China Pharma Holdings, Inc. stock-summary
stock-summary
China Pharma Holdings, Inc.
Pharmaceuticals & Biotechnology
China Pharma Holdings, Inc. is a holding company. The Company conducts its production, marketing, finance, development and administrative activities through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson) in the People's Republic of China (PRC). It is engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with various diseases and medical conditions in the PRC. It manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions and granules. Its pharmaceutical products are sold on a prescription basis and are approved by the China Food and Drug Administration (the CFDA). The Company manufactured over 20 pharmaceutical products for various diseases and medical indications. It offers products for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases and Others.
Company Coordinates stock-summary
Company Details
2Nd Floor, No. 17, Jinpan Road, Haikou , HAIKOU HAN : 570216
stock-summary
Tel: 86 898 66811730
stock-summary
http://www.chinapharmaholdings.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."